BioMarin Pharmaceutical Inc

Geschlossen

BrancheGesundheitswesen

58.79 1.75

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

58.41

Max

58.99

Schlüsselkennzahlen

By Trading Economics

Einkommen

-34M

106M

Verkäufe

-108M

766M

KGV

Branchendurchschnitt

41.234

56.269

EPS

0.76

Gewinnspanne

13.773

Angestellte

3,221

EBITDA

177M

173M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+47.48% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

679M

11B

Vorheriger Eröffnungskurs

57.04

Vorheriger Schlusskurs

58.79

Nachrichtenstimmung

By Acuity

34%

66%

89 / 342 Ranking in Healthcare

BioMarin Pharmaceutical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juli 2026, 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

1. Juli 2026, 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

30. Juni 2026, 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

29. Juni 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, retracing from earlier gains amid mixed U.S. equity performance and broader inflation concerns.

26. Juni 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25. Juni 2026, 23:31 UTC

Biomarin Pharmaceutical shares declined in after-market trading, despite remaining above the 20-day moving average and near the upper end of its one-month range.

24. Juni 2026, 19:41 UTC

Biomarin Pharmaceutical Inc is gaining Wednesday, supported by strong momentum in the Biotechnology sub-sector, despite an earlier decline in the session.

23. Juni 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. Broader market sentiment is affected by declines in Asian markets amid tech sector concerns.

22. Juni 2026, 23:56 UTC

Biomarin Pharmaceutical shares showed little change in after-market trading. The stock remains within the middle of its one-month trading range.

19. Juni 2026, 00:01 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market hours, recovering from earlier lows and reflecting strong performance since Thursday's close.

18. Juni 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close despite earlier fluctuations in the session.

17. Juni 2026, 20:08 UTC

Event

Biomarin Pharmaceutical is trading lower amid broader market declines, despite presenting new data on VOXZOGO® and BMN 333 at the ENDO 2026 conference.

16. Juni 2026, 23:41 UTC

Event

Biomarin Pharmaceutical presented new data on investigational therapies at the Endocrine Society Annual Meeting. Shares showed little change during after-market hours.

15. Juni 2026, 13:26 UTC

Biomarin Pharmaceutical Inc is trading higher in pre-market hours, reflecting positive momentum amid a broader upward trend in Asian markets, including a surge in the Nikkei Index.

13. Juni 2026, 00:01 UTC

Biomarin Pharmaceutical Inc shares declined in after-market trading, retracing from earlier gains while remaining above the 20-day moving average. No specific news was identified.

12. Juni 2026, 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

11. Juni 2026, 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, reaching an early session low. Broader economic news includes an unexpected rise in initial jobless claims.

10. Juni 2026, 20:03 UTC

Biomarin Pharmaceutical shares are lower today, reflecting broader market trends amid volatility. The stock peaked earlier in the session before declining significantly.

9. Juni 2026, 20:03 UTC

Biomarin Pharmaceutical Inc shares are higher, reaching a session high and trading above its 20-day moving average. No specific news was identified for the move.

8. Juni 2026, 22:51 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, reflecting a notable decline despite a broader rebound in US stocks, particularly in the semiconductor sector.

5. Juni 2026, 20:07 UTC

Biomarin Pharmaceutical Inc shares are modestly higher, reflecting broader market gains amid robust job growth data. No specific company news was identified.

4. Juni 2026, 22:31 UTC

Biomarin Pharmaceutical Inc is trading lower in after-market hours amid a broader market decline and rising U.S. Treasury yields impacting biotechnology stocks.

3. Juni 2026, 20:06 UTC

Biomarin Pharmaceutical shares are higher amid broader market strength following a positive ADP Employment Report, which showed job growth exceeding expectations.

2. Juni 2026, 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, continuing a decline since Monday. The stock closed at its lowest point after an early high.

1. Juni 2026, 23:03 UTC

Biomarin Pharmaceutical shares declined in after-market trading, continuing a downward trend since Monday's close, despite remaining above the 20-day moving average.

29. Mai 2026, 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid routine trading patterns.

28. Mai 2026, 22:36 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting notable movement since Thursday's close amid broader market dynamics and economic data.

27. Mai 2026, 19:41 UTC

Biomarin Pharmaceutical Inc shares are lower Wednesday, reversing recent gains. No specific news was identified to explain the decline since Tuesday's close.

26. Mai 2026, 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from a recent trend of higher closes amid rising bond yields and no specific company news.

Peer-Vergleich

Kursveränderung

BioMarin Pharmaceutical Inc Prognose

Kursziel

By TipRanks

47.48% Vorteil

12-Monats-Prognose

Durchschnitt 87 USD  47.48%

Hoch 120 USD

Tief 50 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioMarin Pharmaceutical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

15

Buy

5

Halten

0

Sell

Stimmung

By Acuity

89 / 342 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat